BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
Volume 0.09M
Average 0.07M
BSEM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BioStem Technologies, Inc.NASDAQ: BSEM
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 77.4% from a year ago
Cash & equivalents stood at $6.96M at the end of Q2 FY2026, down 77.4% from a year earlier and down 49.2% from the prior quarter. Over 3 fiscal years it compounded at +237.0% a year.
Context
- Cash & equivalents amounted to 14.3% of total assets at the end of Q2 FY2026, down 13.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -77.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 29.55M USD
- Year-over-year change
- +29.4%
- 4-year CAGR
- +205.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.55M | +29.4% |
| FY2024 | 2024-12-31 | 22.83M | +9437.2% |
| FY2023 | 2023-12-31 | 239.41K | -69.0% |
| FY2022 | 2022-12-31 | 772.14K | +126.9% |
| FY2021 | 2021-12-31 | 340.33K | — |
Cash & Equivalents vs competitors
How BSEM compares with its peers on the latest reported figures
No competitor Cash & Equivalents figures are available to compare.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 340.33K | 772.14K | 239.41K | 22.83M | 29.55M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 300.14K | 37.21K | 11.37M | 106.23M | 9.87M |
| Inventory | 260.05K | 395.23K | 658.68K | 1.82M | 2.88M |
| Other Current Assets | 0 | 0 | 329.24K | 2.87M | 2.1M |
| Total Current Assets | 938.6K | 1.49M | 12.6M | 133.76M | 44.4M |
| Property, Plant & Equipment (Net) | 1.28M | 1.37M | 1.37M | 1.97M | 5.26M |
| Goodwill | 244.64K | 244.64K | 244.64K | 244.64K | 244.64K |
| Intangible Assets | 210.05K | 362.57K | 347.6K | 224.14K | 119.77K |
| Long-term Investments | 0 | 0 | (347.6K) | 0 | 0 |
| Tax Assets | 0 | 110.95K | 0 | 4.35M | 0 |
| Other Non-current Assets | 0 | (110.95K) | 347.6K | 0 | 0 |
| Total Non-current Assets | 1.73M | 1.98M | 1.96M | 6.79M | 5.62M |
| Total Assets | 2.67M | 3.47M | 14.56M | 140.55M | 50.03M |
| Account Payables | 647.26K | 48.64K | 1.39M | 5.29M | 4.44M |
| Short-term Debt | 3M | 4.04M | 4.45M | 4.06M | 3.23M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.47M | 8.06K | 8.73K | 0 | 0 |
| Other Current Liabilities | (903.79K) | 150.54K | 245.02K | 86.8M | 977.27K |
| Total Current Liabilities | 6.54M | 6.33M | 15.62M | 99.17M | 10.78M |
| Long-term Debt | 1.8M | 1.03M | 265.64K | 150K | 0 |
| Deferred Tax Liabilities | 0 | 110.95K | 0 | 174.27K | 0 |
| Deferred Revenue (Non-current) | 0 | (110.95K) | 0 | 0 | 0 |
| Other Non-current Liabilities | 120.21K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 1.92M | 1.09M | 283.78K | 504.5K | 105.26K |
| Total Liabilities | 8.47M | 7.42M | 15.9M | 99.67M | 10.89M |
| Common Stock | 9.74K | 12.16K | 16.22K | 16.66K | 16.83K |
| Retained Earnings | (29.95M) | (37.02M) | (45.62M) | (13.74M) | (21.17M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 165.29K | 126.44K | 0 | 0 | 0 |
| Total Equity | (5.79M) | (3.95M) | (1.34M) | 40.88M | 39.14M |
| Total Debt | 4.83M | 5.21M | 4.77M | 4.5M | 3.33M |
| Net Debt | 4.49M | 4.32M | 4.53M | (18.33M) | (26.22M) |
BioStem Technologies, Inc.
NASDAQ:BSEM
Intrinsic Alpha fair value
Locked
Current Price
$3.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.